Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Arch Pediatr ; 29(6): 415-423, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1866883

ABSTRACT

BACKGROUND: COVID-19 and lysosomal storage disorders (LSDs) share a common immunological pathway as they cause the release of cytokines in a similar pattern. We aimed to evaluate the immunity status and reveal the course of COVID-19 in patients with LSDs. RESULTS: The median age of 110 patients with LSDs was 129 months (range: 21-655), and all but one patient with mucopolysaccharidosis (MPS) type III were regularly receiving enzyme replacement therapy (ERT). In 53.6% (n = 56) of the patients (23 patients with Gaucher disease [10 type III, 13 type I], 26 patients with MPS [8 type VI, 11 type IVA, 1 type III, 3 type II, and 3 type I], and 7 patients with Pompe disease), an abnormality in at least one of the autoimmunity or immunodeficiency parameters was reported. Furthermore, 12 (57%) of 21 Gaucher cases (7 type III, 5 type I), 18 (40.9%) of 44 MPS cases (9 type IVA, 5 type VI, 1 type I, 2 type II, and 1 type III), and six (66%) of nine Pompe cases were reported to involve abnormalities in at least one of the parameters related to immunodeficiency. Immunoglobulin (Ig) M and IgA levels were reported to be lower, and there were abnormalities in the lymphocyte counts and subgroups in the MPS group. ANA was reported to be positive in one patient with Gaucher type III, anti-DNA in two patients with Gaucher type I and one patient with MPS type VI, antithyroglobulin in two patients with Gaucher type I, anti-TPO in one patient with Gaucher type I, TRAB in one patient with Gaucher type I, antiphospholipid IgM in three patients with Gaucher type III and one patient with Gaucher type I, anticardiolipin IgM in one patient with Gaucher type I, one patient with Gaucher type III, and one patient with MPS type II. However, no clinical presentation was consistent with the laboratory results except for one patient with Gaucher type I disease with Hashimoto thyroiditis. Two of the four patients who survived the COVID-19 infection with mild symptoms had a diagnosis of Gaucher type I, and no abnormality was detected in their laboratory tests. The other two patients had a diagnosis of MPS types VI and II. Immune dysfunction was detected in the patient with a diagnosis of MPS type II. Four of our patients were discharged without any sequelae. CONCLUSION: Problems with immunity did not cause any noticeable clinical results. Being well protected by reducing social contact might have played a role. However, we believe that it should be borne in mind that cardiac and pulmonary involvement, as well as immune dysfunction in LSDs, may cause an increased need for intensive care because of secondary bacterial infections.


Subject(s)
COVID-19 , Glycogen Storage Disease Type II , Lysosomal Storage Diseases , COVID-19/epidemiology , Enzyme Replacement Therapy/methods , Glycogen Storage Disease Type II/diagnosis , Glycogen Storage Disease Type II/drug therapy , Humans , Immunoglobulin M/therapeutic use , Lysosomal Storage Diseases/diagnosis , Lysosomal Storage Diseases/drug therapy , Lysosomal Storage Diseases/genetics , Turkey/epidemiology
2.
Gazi Medical Journal ; 32(4 A):17, 2020.
Article in English | EMBASE | ID: covidwho-1192877

ABSTRACT

Objective: Due to the rapid spread of a novel coronavirus (SARS-CoV-2) globally, the WHO declared the situation as a pandemic. ACE2 is crucial for SARS-CoV-2 attachment onto the host cells. The expression levels and variations of ACE2 may facilitate or slow down the entrance of the SARS-CoV-2 virus into host cells. This might explain the variability of infection through individuals and populations. Materials-Methods: In this study, a retrospective comparative WES analysis of the ACE2 variants was conducted to 584 individuals around Turkey. Allele frequencies of all variants were calculated and filtered to remove variants with allele frequencies lower than 0.003. Results: The variants that showed a susceptibility to SARS-CoV-2 transmission in the literature were compared with our data. The most frequent variant, ACE2 N720D, and the second most frequent variant, ACE2 K26R that alters ACE2 protein and enhances its affinity for SARS-CoV-2 are not frequent in the Turkish population. Conclusion: The main ACE variants that has susceptibility effect to SARS-CoV-2 were not determined. It shows that the Turkish genetic makeup lacks any ACE2 variant that increases susceptibility for SARS-CoV-2 infection. Overall, this study will contribute to the formation of a national variation database and may also contribute to further studies of SARS-CoV-2 infection.

SELECTION OF CITATIONS
SEARCH DETAIL